top of page

Search Results

Cerca in questo sito

548 risultati trovati con una ricerca vuota

  • Fresenius and WuXi Biologics agree development partnership covering up to 37 biosimilar candidates

    Fresenius has entered an exclusive development agreement with WuXi Biologics covering options for up to 37 biosimilar candidates, potentially more than doubling its combined marketed and pipeline portfolio. The agreement, announced on 2 November 2026, allows Fresenius to select biosimilar development programmes over the next decade while retaining exclusive global commercialisation rights and compensating WuXi Biologics through a fee-for-service development structure. Initial targets include biosimilars referencing polatuzumab vedotin and teprotumumab, with the originator products across the potential portfolio representing more than €370 billion in aggregate sales rather than a disclosed transaction value. Field Content Article Type Deals Company Fresenius Partner WuXi Biologics Deal Type Exclusive biosimilar development agreement Announcement Date 2 November 2026 Agreement Duration Up to 10 years for candidate selection Maximum Potential Biosimilar Candidates 37 Existing Marketed and Pipeline Portfolio 29 molecules Potential Expanded Portfolio 66 molecules Development Structure Fresenius may select individual biosimilar development programmes Partner Responsibilities WuXi Biologics provides development services for selected programmes Commercialisation Rights Fresenius retains exclusive global commercialisation rights Payment Structure Fee-for-service development payments Financial Consideration Not quantified in supplied summary Referenced Originator Product Sales More than €370 billion in aggregate sales Originator Sales Clarification Aggregate originator product sales are not the agreement's financial value Initial Reference Product Polatuzumab vedotin Additional Reference Product Teprotumumab Product Category Biosimilars Therapeutic Areas Potential oncology and other specialty biologic indications Geographic Scope Global commercialisation rights Regulatory Status No new biosimilar approvals announced Transaction Distinction Options covering up to 37 development candidates; not 37 completed acquisitions or approved products What Happened Fresenius and WuXi Biologics agreed an exclusive development framework covering up to 37 potential biosimilar candidates. Why It Matters The agreement could substantially expand Fresenius' biosimilar portfolio and strengthen its long-term position in global biologics competition. Strategic Rationale Use external development capabilities to accelerate biosimilar pipeline expansion while retaining worldwide commercialisation rights. Key Takeaway Fresenius has secured options to develop up to 37 biosimilars, with programme-specific payments and no disclosed aggregate deal value. What to Watch Candidate selection, development timelines, regulatory submissions, manufacturing arrangements and future biosimilar launches. Primary Source Fresenius Primary Source URL https://www.fresenius.com/node/7451 Relevant Date 2 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Sun Pharma Ilumya for adults with active psoriatic arthritis

    The FDA has approved Sun Pharma's Ilumya for adults with active psoriatic arthritis, expanding the IL-23 inhibitor beyond its established plaque psoriasis indication. Ilumya (tildrakizumab-asmn) received a supplemental biologics licence approval for active psoriatic arthritis following Phase III INSPIRE-1 and INSPIRE-2 studies that met their primary ACR20 response endpoints at week 24. The new indication extends the medicine's use to inflammatory joint disease while retaining healthcare professional administration, providing another approved IL-23-targeted treatment option for eligible adults in the United States. Field Content Article Type Approvals Company Sun Pharma Product Ilumya Generic Name Tildrakizumab-asmn Modality Monoclonal antibody Mechanism of Action Interleukin-23 inhibition Regulator U.S. Food and Drug Administration Approval Type Supplemental biologics licence approval Approval Announcement Date 30 October 2026 New Indication Active psoriatic arthritis Patient Population Adults with active psoriatic arthritis Therapeutic Area Rheumatology; immunology Previously Approved Indication Plaque psoriasis Clinical Studies INSPIRE-1; INSPIRE-2 Study Phase Phase III Study Design Placebo-controlled clinical studies Primary Endpoint ACR20 response at week 24 Clinical Results Both INSPIRE-1 and INSPIRE-2 met their primary ACR20 endpoints at week 24 Numerical ACR20 Response Rates Not confirmed in supplied summary Administration Administered by a healthcare professional Patient Self-Injection Not described as a self-injection product Geographic Scope United States What Happened The FDA expanded Ilumya's approved indications to include adults with active psoriatic arthritis. Why It Matters The decision provides an additional IL-23-targeted treatment option for inflammatory joint disease and broadens Ilumya's clinical use beyond plaque psoriasis. Clinical Evidence Two Phase III placebo-controlled studies met their primary ACR20 response endpoints at week 24. Key Takeaway Ilumya now has a distinct US psoriatic arthritis indication supported by positive Phase III clinical evidence. What to Watch Prescribing information, clinical guideline positioning, payer coverage, rheumatologist adoption and long-term safety outcomes. Primary Source Sun Pharma via PR Newswire Primary Source URL https://www.prnewswire.com/news-releases/ilumya-tildrakizumab-asmn-approved-in-the-us-for-the-treatment-of-adults-with-active-psoriatic-arthritis-302924320.html Relevant Date 30 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • European Commission approves Enhertu for residual HER2-positive early breast cancer after neoadjuvant therapy

    The European Commission has approved Enhertu for patients with residual HER2-positive early breast cancer, extending the antibody-drug conjugate into a curative-intent treatment setting. AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) is now authorised as adjuvant therapy for adults with resected HER2-positive early breast cancer who have residual invasive disease following neoadjuvant taxane-based chemotherapy and HER2-targeted treatment. The approval is supported by Phase III DESTINY-Breast05 results showing a 53% reduction in the risk of invasive disease recurrence or death compared with trastuzumab emtansine, establishing Enhertu's first European authorisation in the early breast cancer setting. Field Content Article Type Approvals Companies AstraZeneca; Daiichi Sankyo Product Enhertu Generic Name Trastuzumab deruxtecan Modality HER2-directed antibody-drug conjugate Regulator European Commission Approval Type Marketing authorisation for an additional indication Approval Announcement Date 27 October 2026 Indication Adjuvant treatment of HER2-positive early breast cancer with residual invasive disease following neoadjuvant therapy Patient Population Adults with resected HER2-positive early breast cancer and residual invasive disease Disease Setting Early breast cancer; postoperative adjuvant treatment Prior Treatment Requirement Neoadjuvant taxane-based chemotherapy and HER2-targeted therapy Treatment Intent Curative intent Biomarker HER2-positive Clinical Study DESTINY-Breast05 Study Phase Phase III Comparator Trastuzumab emtansine (T-DM1) Primary Reported Outcome 53% reduction in the risk of invasive disease recurrence or death compared with T-DM1 Clinical Endpoint Invasive disease-free survival Geographic Scope European Union Previous Treatment Settings Previously authorised advanced breast cancer indications Regulatory Significance First EU approval of Enhertu in early breast cancer What Happened The European Commission authorised Enhertu for adjuvant treatment of eligible adults with residual HER2-positive early breast cancer. Why It Matters The approval moves a HER2-directed antibody-drug conjugate into an earlier treatment setting where preventing invasive recurrence is a central clinical objective. Clinical Evidence DESTINY-Breast05 demonstrated a 53% relative reduction in invasive recurrence or death versus T-DM1. Key Takeaway Enhertu has entered the European early breast cancer treatment pathway for patients with residual invasive disease after neoadjuvant therapy. What to Watch European clinical guideline updates, reimbursement decisions, treatment adoption, long-term survival data and safety monitoring. Primary Source AstraZeneca Primary Source URL https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-approved-eu-for-her2-positive-ebc.html Relevant Date 27 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves NRx preservative-free ketamine injection amid US hospital supply shortage

    The FDA has approved NRx Pharmaceuticals' preservative-free generic ketamine injection, adding a US-manufactured supply option during an ongoing shortage of injectable ketamine. The abbreviated new drug application covers a preservative-free ketamine formulation manufactured with Nephron Pharmaceuticals using blow-fill-seal technology and formulated without the preservative benzethonium chloride. NRx reported that commercial supply was available following the 30 October approval announcement, although a specific launch date was not confirmed, and the decision applies to established anaesthesia uses rather than the company's separate investigational depression programme. Field Content Article Type Approvals Company NRx Pharmaceuticals Manufacturing Partner Nephron Pharmaceuticals Product Preservative-free generic ketamine injection Active Ingredient Ketamine Product Type Generic injectable medicine Formulation Preservative-free injection Excluded Preservative Benzethonium chloride Manufacturing Technology Blow-fill-seal Manufacturing Geography United States Regulator U.S. Food and Drug Administration Approval Type Abbreviated new drug application approval Approval Announcement Date 30 October 2026 Approved Therapeutic Use Established ketamine anaesthesia uses Therapeutic Area Anaesthesia Administration Route Injection Supply Context Ketamine injection listed on the FDA drug shortage list at the time of the announcement Commercial Supply Status NRx reported commercial supply on hand Confirmed Commercial Launch Date Not confirmed in supplied summary Investigational Depression Programme Separate from the approved generic anaesthesia product Depression Indication Approval No depression indication approval established by this announcement Geographic Scope United States What Happened The FDA approved an abbreviated new drug application for NRx's preservative-free generic ketamine injection. Why It Matters The approval adds a domestically manufactured injectable ketamine supply option during a reported US drug shortage. Manufacturing Significance The product uses blow-fill-seal technology and excludes benzethonium chloride. Key Takeaway NRx secured FDA approval for a preservative-free generic ketamine product for established anaesthesia uses, not for its investigational depression programme. What to Watch Confirmed commercial launch, hospital distribution, production capacity, shortage-list status and product availability. Primary Source NRx Pharmaceuticals Primary Source URL https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-nasdaqnrxp-receives-fda-approval Relevant Date 30 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA grants accelerated approval to Inovio Voceryq as first US plasmid DNA-based immunotherapy

    The FDA has granted accelerated approval to Inovio's Voceryq, marking the first US authorisation of a plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis. Voceryq is designed to reduce the frequency of surgical papilloma removal in adults with HPV-associated recurrent respiratory papillomatosis and is administered using Inovio's CELLECTRA 5PSP electroporation device. In the RRP-001 study, 7 of 26 efficacy-evaluable patients, approximately 27%, required no surgery during 12 months of follow-up, while continued marketing authorisation remains dependent on confirmatory evidence under the FDA's accelerated approval pathway. Field Content Article Type Approvals Company Inovio Pharmaceuticals Product Voceryq Modality Plasmid DNA-based immunotherapy Regulator U.S. Food and Drug Administration Approval Type Accelerated approval Approval Date 30 October 2026 Regulatory Milestone First plasmid DNA-based immunotherapy approved in the United States Indication Recurrent respiratory papillomatosis in adults Disease Cause Human papillomavirus infection Patient Population Adults with recurrent respiratory papillomatosis Treatment Objective Reduce the frequency of surgical papilloma excisions Administration Technology CELLECTRA 5PSP electroporation device Clinical Study RRP-001 Efficacy-Evaluable Population 26 patients Surgery-Free Patients 7 of 26 patients Reported Surgery-Free Proportion Approximately 27% Reported Follow-Up 12 months Regulatory Condition Continued approval contingent on confirmatory evidence Geographic Scope United States What Happened The FDA granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis. Why It Matters The decision introduces the first FDA-approved plasmid DNA-based immunotherapy and a treatment approach intended to reduce repeated surgical interventions. Clinical Evidence In RRP-001, seven of 26 efficacy-evaluable patients required no surgery during 12 months of follow-up. Key Takeaway Voceryq establishes a new therapeutic modality in US regulatory practice, although confirmatory evidence remains necessary. What to Watch Confirmatory clinical evidence, treatment adoption, durability of reduced surgical burden and post-approval safety monitoring. Primary Source U.S. Food and Drug Administration Primary Source URL https://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis Relevant Date 30 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Astellas signs option and licensing agreement with Audax Biosciences worth up to $1.34bn for cancer therapy DAX-044

    Astellas secures an exclusive global option to license Audax Biosciences' investigational IL-12 fusion therapy DAX-044 Astellas has entered an exclusive option and licensing agreement with Australian biotechnology company Audax Biosciences for DAX-044, an investigational immune-targeted IL-12 antibody-cytokine fusion therapy being developed for cancer treatment. The agreement could be worth up to US$1.34bn excluding royalties, giving Astellas the opportunity to expand its immuno-oncology pipeline through a novel approach designed to direct IL-12 activity towards tumour-associated immune cells. Field Content Alert Type Option and licensing agreement Article Type Deals Companies Astellas Pharma; Audax Biosciences Deal Type Exclusive global option and licensing agreement Asset or Company DAX-044 Therapy Area(s) Oncology; immuno-oncology Technology or Modality Immune-targeted interleukin-12 (IL-12) antibody-cytokine fusion therapy Deal Value Up to US$1.34bn in potential transaction value, excluding royalties; individual payment components not specified in the supplied information Development Stage (if relevant) Investigational development-stage therapy; precise clinical stage not established in the supplied information Geography Japan; Australia; worldwide licensing rights What Happened Astellas entered an exclusive option and licensing agreement with Australian biotechnology company Audax Biosciences covering DAX-044, an investigational immune-targeted IL-12 antibody-cytokine fusion therapy for immuno-oncology. The agreement grants Astellas an exclusive option to license the programme worldwide. Why It Matters The agreement gives Astellas access to a differentiated immuno-oncology approach and represents a significant potential commercial opportunity for Australian biotechnology innovation. The transaction highlights continued pharmaceutical interest in therapies designed to improve the targeting of immune activation in cancer treatment. Supporting Context IL-12 is an immune-signalling cytokine involved in stimulating anti-tumour immune responses. Targeted antibody-cytokine fusion approaches aim to concentrate immune activity in relevant biological environments while potentially limiting unwanted systemic exposure. Strategic Rationale (optional) Astellas can evaluate a novel immune-targeted cytokine platform before exercising its global licensing option, while Audax gains a potential international development and commercialisation partner. Potential Impact (optional) If successfully developed, DAX-044 could contribute to emerging immuno-oncology treatment strategies using targeted cytokine delivery. Clinical efficacy, safety and regulatory outcomes remain to be established. Key Takeaway Astellas' agreement with Audax Biosciences provides an exclusive worldwide licensing option for DAX-044 in a potential US$1.34bn immuno-oncology transaction, excluding royalties. What to Watch (optional) Astellas' decision on exercising the licensing option, further development milestones, emerging safety and efficacy data, and subsequent clinical progression of DAX-044. Primary Source https://newsroom.astellas.com/2026-10-28-astellas-and-audax-biosciences-enter-exclusive-option-and-license-agreement-for-dax-044-a-novel-immune-targeted-il-12-antibody-cytokine-fusion-for-immuno-oncology Relevant Date 28 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Anthropic acquires Mithril Medicine and expands AI-driven drug discovery partnerships

    Anthropic has acquired Mithril Medicine and established multiple life sciences research collaborations, moving beyond AI tools into direct participation in experimental drug discovery. The acquisition brings Mithril Medicine, a one-person biotechnology company researching therapies for two rare forms of muscular dystrophy, into Anthropic's drug discovery activities alongside founder Cody Tranbarger. Anthropic also disclosed collaborations with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group, although acquisition consideration and individual partnership economics were not disclosed. Field Content Article Type Deals Acquirer Anthropic Acquired Company Mithril Medicine Deal Type Biotechnology company acquisition and research collaboration expansion Announcement Date 27 October 2026 Acquisition Status Acquisition confirmed Acquired Company Profile One-person biotechnology startup Founder Cody Tranbarger Founder Integration Joined Anthropic's drug discovery efforts Research Focus Experimental treatments for two rare forms of muscular dystrophy Specific Muscular Dystrophy Subtypes Not confirmed in supplied summary Acquisition Consideration Not disclosed Acquired Programme Development Stage Predominantly preclinical Research Collaboration Partners BigHat Biosciences; Bristol Myers Squibb; Divergence Labs; Enveda; Generate Biomedicines; The Column Group Collaboration Focus Applications of AI to drug discovery and life sciences research Individual Collaboration Economics Not disclosed Strategic Expansion Direct involvement in experimental drug discovery programmes alongside AI research collaborations Regulatory Status No new drug regulatory approval announced What Happened Anthropic acquired Mithril Medicine and announced multiple collaborations with biotechnology and pharmaceutical research organisations. Why It Matters The acquisition signals growing involvement by frontier AI developers in experimental therapeutic discovery and the integration of AI capabilities with biotechnology research. Strategic Rationale Apply Anthropic's AI capabilities to drug discovery research while expanding relationships across the life sciences ecosystem. Key Takeaway Anthropic has entered biotechnology asset ownership through Mithril Medicine while broadening its drug discovery collaboration network; financial terms remain undisclosed. What to Watch Progress of acquired research programmes, collaboration outputs, scientific validation, additional partnerships and future clinical development. Primary Source Anthropic Primary Source URL https://www.anthropic.com/research/early-progress-drug-development Relevant Date 27 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA expands Instylla Embrace Hydrogel Embolic System approval to peripheral arterial bleeding

    The FDA has expanded approval of Instylla's Embrace Hydrogel Embolic System to peripheral arterial bleeding, supported by clinical evidence from the multicentre HALT study. The expanded premarket approval authorises the Embrace Hydrogel Embolic System for embolisation of peripheral arterial bleeding in vessels measuring 6 mm or less, extending its previously approved use in hypervascular tumour embolisation. In the prospective HALT study involving 130 patients across 22 US sites, the company reported 90% clinical success and 100% freedom from major adverse events through 30 days, supporting the device's additional indication. Field Content Article Type Approvals Regulatory Authority U.S. Food and Drug Administration Regulatory Decision Expanded premarket approval indication Approval Announcement Date 29 October 2026 Company Instylla Device Name Embrace Hydrogel Embolic System Device Type Hydrogel embolisation system Therapeutic Area Interventional radiology; vascular intervention New Approved Indication Embolisation of peripheral arterial bleeding Eligible Vessel Size 6 mm or less Previous Approved Indication Hypervascular tumour embolisation Previous Approval Date August 2025 Supporting Clinical Study HALT Study Design Prospective multicentre clinical study Study Population 130 patients Study Sites 22 US sites Reported Clinical Success 90% Reported Major Adverse Event Outcome 100% freedom from major adverse events through 30 days Follow-up Period 30 days for reported major adverse event outcome Geography United States What Happened The FDA expanded the Embrace Hydrogel Embolic System's premarket approval to include peripheral arterial bleeding in vessels measuring 6 mm or less. Why It Matters The new indication broadens embolisation options for interventional specialists managing peripheral arterial bleeding. Clinical Evidence HALT enrolled 130 patients at 22 US centres and reported 90% clinical success and 100% freedom from major adverse events through 30 days. Regulatory Distinction This is an additional approved indication for an existing device, not its initial FDA approval. Key Takeaway Instylla's Embrace system can now be used for approved peripheral arterial bleeding procedures in eligible vessels. What to Watch Hospital adoption, physician training, reimbursement, real-world safety, procedural outcomes and further clinical evidence. Primary Source Instylla via PR Newswire Primary Source URL https://www.prnewswire.com/news-releases/instyllas-embrace-hydrogel-embolic-system-receives-fda-approval-for-peripheral-arterial-bleeds-302922926.html Relevant Date 29 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Flagship Pioneering merges Cellarity, Etiome and Empress platforms to launch AI drug discovery company Etcelera

    Flagship Pioneering has formed Etcelera by combining three biotechnology platforms with AI capabilities to develop a causal-intelligence approach to drug discovery. The new company integrates technologies from Cellarity, Etiome and Empress Therapeutics, combining transcriptomic, chemoproteomic and perturbation data to investigate disease mechanisms and predict therapeutic effects. Etcelera will be led by Ad Rawcliffe with continued support from Flagship Pioneering and other backers, while the announcement did not disclose a transaction valuation or financial terms for the platform combination. Field Content Article Type Deals Formation Sponsor Flagship Pioneering New Company Etcelera Deal Type Biotechnology platform combination and company formation Announcement Date 29 October 2026 Contributing Platforms Cellarity; Etiome; Empress Therapeutics Technology Focus AI-enabled causal intelligence for drug discovery Scientific Approach Integrating biological data to investigate causal disease mechanisms and predict treatment effects Data Modalities Transcriptomic; chemoproteomic; perturbation data Therapeutic Area Drug discovery across potential disease areas Chief Executive Ad Rawcliffe Financial Backing Flagship Pioneering and other supporters Transaction Valuation Not disclosed Financial Terms Not disclosed Specific Lead Drug Candidate Not confirmed in supplied summary Clinical Development Status No specific clinical programme status confirmed in supplied summary Strategic Objective Move drug discovery toward predictive understanding of disease mechanisms and therapeutic responses What Happened Flagship Pioneering formed Etcelera by combining the technologies of Cellarity, Etiome and Empress Therapeutics with proprietary AI capabilities. Why It Matters The platform combination brings multiple experimental and computational approaches together to support more integrated, mechanism-focused drug discovery. Strategic Rationale Unify complementary biotechnology platforms and AI capabilities to improve the identification and evaluation of therapeutic opportunities. Regulatory Status No new drug approval or clinical authorisation announced Key Takeaway Etcelera combines three Flagship-linked biotechnology platforms into a new AI-enabled drug discovery company, with financial terms undisclosed. What to Watch Platform validation, pipeline disclosures, research partnerships, financing, leadership appointments and future clinical candidates. Primary Source Flagship Pioneering Primary Source URL https://www.flagshippioneering.com/news/press-release/flagship-pioneering-forms-etcelera-to-move-drug-discovery-from-probability-to-prediction Relevant Date 29 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves STADA and Xbrane Lucamzi ranibizumab biosimilar for retinal diseases

    The FDA has approved Lucamzi, a ranibizumab biosimilar developed by Xbrane Biopharma and commercialised through STADA, expanding treatment competition in retinal diseases. Lucamzi (ranibizumab-blrz) has received US FDA approval as a biosimilar to Lucentis for retinal conditions including neovascular age-related macular degeneration, adding another treatment option within the established ranibizumab market. Confirmed in STADA's announcement dated 29 October 2026, the decision strengthens the companies' US ophthalmology portfolio and introduces an additional biosimilar competitor without representing the first US approval of a ranibizumab biosimilar. Field Content Article Type Approvals Regulatory Authority U.S. Food and Drug Administration Regulatory Decision Biosimilar approval Approval Announcement Date 29 October 2026 Product Name Lucamzi Nonproprietary Name Ranibizumab-blrz Reference Product Lucentis Product Type Ranibizumab biosimilar Developer Xbrane Biopharma Commercial Partner STADA Therapeutic Area Ophthalmology; retinal diseases Approved Indication Highlight Neovascular age-related macular degeneration Other Approved Indications Full indication list not confirmed in supplied summary Geography United States Administration Intravitreal administration Regulatory Significance Additional FDA-approved ranibizumab biosimilar; not the first US ranibizumab biosimilar Regulatory Date Clarification Approval confirmed in STADA announcement dated 29 October 2026 after an earlier publication-date discrepancy Commercial Launch Date Not confirmed in supplied summary Pricing Not disclosed What Happened The FDA approved Lucamzi as a biosimilar to Lucentis for retinal diseases including neovascular age-related macular degeneration. Why It Matters The approval expands biosimilar competition in the US retinal disease treatment market and may increase treatment choice and pricing competition. Commercial Context Xbrane developed the biosimilar and STADA participates in its US commercialisation arrangements. Key Takeaway Lucamzi has received FDA approval as an additional ranibizumab biosimilar for retinal diseases. What to Watch US commercial launch, pricing, reimbursement, ophthalmologist adoption, supply arrangements and market share. Primary Source STADA Primary Source URL https://www.stada.com/blog/posts/2026/october/fda-approves-lucamzi-biosimilar-to-lucentis Relevant Date 29 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Aptar Pharma acquires Pulmotree to expand next-generation pulmonary drug delivery technology

    Aptar Pharma has acquired German inhalation technology specialist Pulmotree, adding its Kolibri platform to expand next-generation pulmonary drug delivery capabilities. The acquisition follows an existing collaboration and brings Pulmotree's Kolibri Non-Propellant Liquid Inhaler technology into Aptar Pharma's respiratory portfolio, supporting targeted delivery of inhaled medicines. Aptar intends to accelerate development, industrialisation and commercialisation of the platform, including potential applications for complex therapeutic molecules such as biologics, although the acquisition's financial terms were not disclosed. Field Content Article Type Deals Acquirer Aptar Pharma Acquired Company Pulmotree Deal Type Strategic acquisition Transaction Status Announced as acquired Announcement Date 26 October 2026 Target Company Location Germany Acquired Technology Kolibri Non-Propellant Liquid Inhaler platform Technology Category Pulmonary drug delivery Delivery Approach Non-propellant liquid inhalation Therapeutic Applications Respiratory medicines and potential complex-molecule therapies Potential Molecule Types Biologics and other complex therapeutic molecules Prior Relationship Existing Aptar Pharma-Pulmotree collaboration Strategic Focus Development, industrialisation and commercialisation of next-generation inhalation technology Acquisition Consideration Not disclosed Financial Terms Not disclosed Regulatory Approval Status No new medicine or device regulatory approval established by the acquisition announcement What Happened Aptar Pharma acquired Pulmotree and its Kolibri inhalation technology following an established collaboration. Why It Matters The acquisition broadens Aptar's respiratory drug delivery capabilities and could support development of inhaled treatments involving complex molecules. Strategic Rationale Integrate specialised pulmonary delivery technology to accelerate platform development and commercialisation. Portfolio Impact Adds the Kolibri Non-Propellant Liquid Inhaler platform to Aptar Pharma's technology portfolio. Key Takeaway Aptar has expanded its pulmonary drug delivery portfolio through the acquisition of Pulmotree; the purchase price was not disclosed. What to Watch Kolibri development milestones, industrial scale-up, pharmaceutical partnerships, regulatory progress and commercial adoption. Primary Source Aptar Pharma Primary Source URL https://www.aptar.com/news-events/aptar-pharma-acquires-pulmotree-expanding-growth-opportunities-in-next-generation-pulmonary-drug Relevant Date 26 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Teva acquires BioXcel neuroscience assets including BXCL501 for up to $125 million

    Teva has acquired worldwide rights to BioXcel's BXCL501 neuroscience programme and approved IGALMI product in an asset transaction worth up to $125 million. The completed acquisition transfers specified BioXcel Therapeutics assets to Teva, including investigational BXCL501 dexmedetomidine sublingual film and the FDA-approved hospital-use product IGALMI, following a US bankruptcy court-supervised sale. Teva will pay $57.5 million upfront and may make up to $67.5 million in additional regulatory and sales-related payments, while BXCL501 remains under FDA review for potential at-home treatment of acute agitation associated with schizophrenia or bipolar disorder in adults. Field Content Article Type Deals Acquirer Teva Pharmaceutical Industries Asset Seller BioXcel Therapeutics Deal Type Acquisition of specified pharmaceutical assets and worldwide rights Transaction Status Completed Announcement Date 27 October 2026 Transaction Process US bankruptcy court-supervised asset sale Acquired Development Asset BXCL501 Acquired Approved Product IGALMI Active Ingredient Dexmedetomidine Drug Formulation Sublingual film Therapeutic Area Neuroscience; psychiatry Investigational Indication At-home treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults Existing Approved Use IGALMI for hospital-use treatment of acute agitation in its approved patient population BXCL501 Regulatory Status Under FDA review for proposed at-home use; not approved for that use in supplied summary Acquired Rights Worldwide rights to specified assets Upfront Payment $57.5 million Contingent Payments Up to $67.5 million Maximum Transaction Value Up to $125 million Contingent Payment Triggers Regulatory and sales-related milestones Company Acquisition Status Teva acquired specified assets, not BioXcel Therapeutics as a company What Happened Teva completed an acquisition of BioXcel neuroscience assets following a bankruptcy court-supervised sale. Why It Matters The transaction strengthens Teva's neuroscience portfolio with an approved agitation treatment and a related investigational at-home treatment opportunity. Strategic Rationale Expand Teva's innovative neuroscience pipeline and potential treatment options for acute agitation. Key Takeaway Teva secured worldwide rights to BXCL501 and IGALMI for $57.5 million upfront plus up to $67.5 million in contingent payments. What to Watch FDA review of the proposed at-home indication, regulatory decisions, product integration, commercial development and milestone achievement. Primary Source Teva Pharmaceutical Industries Primary Source URL https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Acquires-Worldwide-Rights-to-BXCL501-Further-Expanding-Innovative-Neuroscience-Pipeline/default.aspx Relevant Date 27 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

bottom of page